ARCHIVES

FDA Sets High Bar for Prevention Agents as ODAC Votes Down Proscar And Avodart

This article is from The Cancer Letter archive.

Vol. 36 No. 44 | December 3, 2010

Download PDF Visit The Full Archive

Related Articles

Non-Profit Spent $1.3 Million On Consultants.

March 28, 2008

A.D. Little Gets 42.4 Million Contract Award

May 2, 1975

Retrospective Data Clean-up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”

March 8, 2002

The President’s Cancer Panel publishes its annual report

May 6, 2011

In Brief: Wyeth-Ayerst To donate hormone Replacement Therapy To NIH For Women’s Health Initiative

April 23, 1993

GAO Report To Include Some But Not all Of Obey’s Charges

June 24, 1977